Intrarenal Delivery of Mesenchymal Stem Cells and Endothelial Progenitor Cells Attenuates Hypertensive Cardiomyopathy in Experimental Renovascular Hypertension

Renovascular hypertension (RVH) leads to left ventricular (LV) hypertrophy and diastolic dysfunction, associated with increased cardiovascular mortality. Intrarenal delivery of endothelial progenitor cells (EPCs) and mesenchymal stem cells (MSCs) improves kidney function in porcine RVH, and the pote...

Full description

Bibliographic Details
Main Authors: Alfonso Eirin, Xiang-Yang Zhu, Behzad Ebrahimi, James D. Krier, Scott M. Riester, Andre J. Van Wijnen, Amir Lerman, Lilach O. Lerman M.D., Ph.D.
Format: Article
Language:English
Published: SAGE Publishing 2015-10-01
Series:Cell Transplantation
Online Access:https://doi.org/10.3727/096368914X685582
id doaj-756296da3b0c4c4da2e26581cd871b58
record_format Article
spelling doaj-756296da3b0c4c4da2e26581cd871b582020-11-25T03:24:36ZengSAGE PublishingCell Transplantation0963-68971555-38922015-10-012410.3727/096368914X685582Intrarenal Delivery of Mesenchymal Stem Cells and Endothelial Progenitor Cells Attenuates Hypertensive Cardiomyopathy in Experimental Renovascular HypertensionAlfonso Eirin0Xiang-Yang Zhu1Behzad Ebrahimi2James D. Krier3Scott M. Riester4Andre J. Van Wijnen5Amir Lerman6Lilach O. Lerman M.D., Ph.D.7Department of Internal Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USADepartment of Internal Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USADepartment of Internal Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USADepartment of Internal Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USADepartment of Orthopedic Surgery, Mayo Clinic, Rochester, MN, USADepartment of Orthopedic Surgery, Mayo Clinic, Rochester, MN, USADivision of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USADivision of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USARenovascular hypertension (RVH) leads to left ventricular (LV) hypertrophy and diastolic dysfunction, associated with increased cardiovascular mortality. Intrarenal delivery of endothelial progenitor cells (EPCs) and mesenchymal stem cells (MSCs) improves kidney function in porcine RVH, and the potent anti-inflammatory properties of MSCs may serve to blunt inflammatory mediators in the cardiorenal axis. However, their relative efficacy in attenuating cardiac injury and dysfunction remains unknown. This study tested the hypothesis that the car-dioprotective effect of EPCs and MSCs delivered into the stenotic kidney in experimental RVH are comparable. Pigs ( n = 7 per group) were studied after 10 weeks of RVH or control untreated or treated with a single intrarenal infusion of autologous EPCs or MSCs 4 weeks earlier. Cardiac and renal function (fast CT) and stenotic kidney release of inflammatory mediators (ELISA) were assessed in vivo, and myocardial inflammation, remodeling, and fibrosis ex vivo. After 10 weeks of RVH, blood pressure was not altered in cell-treated groups, yet stenotic kidney glomerular filtration rate (GFR), blunted in RVH, improved in RVH + EPC, and normalized in RVH + MSCs. Stenotic kidney release of monocyte chemoattractant protein (MCP)-1 and its myocardial expression were elevated in RVH + EPC, but normalized only in RVH + MSC pigs. RVH-induced LV hypertrophy was normalized in both EPC- and MSC-treated pigs, while diastolic function (E/A ratio) was restored to normal levels exclusively in RVH + MSCs. RVH-induced myocardial fibrosis and collagen deposition decreased in RVH + EPCs but further decreased in RVH + MSC-treated pigs. Intrarenal delivery of EPCs or MSCs attenuates RVH-induced myocardial injury, yet MSCs restore diastolic function more effectively than EPCs, possibly by greater improvement in renal function or reduction of MCP-1 release from the stenotic kidney. These observations suggest a therapeutic potential for EPCs and MSCs in preserving the myocardium in chronic experimental RVH.https://doi.org/10.3727/096368914X685582
collection DOAJ
language English
format Article
sources DOAJ
author Alfonso Eirin
Xiang-Yang Zhu
Behzad Ebrahimi
James D. Krier
Scott M. Riester
Andre J. Van Wijnen
Amir Lerman
Lilach O. Lerman M.D., Ph.D.
spellingShingle Alfonso Eirin
Xiang-Yang Zhu
Behzad Ebrahimi
James D. Krier
Scott M. Riester
Andre J. Van Wijnen
Amir Lerman
Lilach O. Lerman M.D., Ph.D.
Intrarenal Delivery of Mesenchymal Stem Cells and Endothelial Progenitor Cells Attenuates Hypertensive Cardiomyopathy in Experimental Renovascular Hypertension
Cell Transplantation
author_facet Alfonso Eirin
Xiang-Yang Zhu
Behzad Ebrahimi
James D. Krier
Scott M. Riester
Andre J. Van Wijnen
Amir Lerman
Lilach O. Lerman M.D., Ph.D.
author_sort Alfonso Eirin
title Intrarenal Delivery of Mesenchymal Stem Cells and Endothelial Progenitor Cells Attenuates Hypertensive Cardiomyopathy in Experimental Renovascular Hypertension
title_short Intrarenal Delivery of Mesenchymal Stem Cells and Endothelial Progenitor Cells Attenuates Hypertensive Cardiomyopathy in Experimental Renovascular Hypertension
title_full Intrarenal Delivery of Mesenchymal Stem Cells and Endothelial Progenitor Cells Attenuates Hypertensive Cardiomyopathy in Experimental Renovascular Hypertension
title_fullStr Intrarenal Delivery of Mesenchymal Stem Cells and Endothelial Progenitor Cells Attenuates Hypertensive Cardiomyopathy in Experimental Renovascular Hypertension
title_full_unstemmed Intrarenal Delivery of Mesenchymal Stem Cells and Endothelial Progenitor Cells Attenuates Hypertensive Cardiomyopathy in Experimental Renovascular Hypertension
title_sort intrarenal delivery of mesenchymal stem cells and endothelial progenitor cells attenuates hypertensive cardiomyopathy in experimental renovascular hypertension
publisher SAGE Publishing
series Cell Transplantation
issn 0963-6897
1555-3892
publishDate 2015-10-01
description Renovascular hypertension (RVH) leads to left ventricular (LV) hypertrophy and diastolic dysfunction, associated with increased cardiovascular mortality. Intrarenal delivery of endothelial progenitor cells (EPCs) and mesenchymal stem cells (MSCs) improves kidney function in porcine RVH, and the potent anti-inflammatory properties of MSCs may serve to blunt inflammatory mediators in the cardiorenal axis. However, their relative efficacy in attenuating cardiac injury and dysfunction remains unknown. This study tested the hypothesis that the car-dioprotective effect of EPCs and MSCs delivered into the stenotic kidney in experimental RVH are comparable. Pigs ( n = 7 per group) were studied after 10 weeks of RVH or control untreated or treated with a single intrarenal infusion of autologous EPCs or MSCs 4 weeks earlier. Cardiac and renal function (fast CT) and stenotic kidney release of inflammatory mediators (ELISA) were assessed in vivo, and myocardial inflammation, remodeling, and fibrosis ex vivo. After 10 weeks of RVH, blood pressure was not altered in cell-treated groups, yet stenotic kidney glomerular filtration rate (GFR), blunted in RVH, improved in RVH + EPC, and normalized in RVH + MSCs. Stenotic kidney release of monocyte chemoattractant protein (MCP)-1 and its myocardial expression were elevated in RVH + EPC, but normalized only in RVH + MSC pigs. RVH-induced LV hypertrophy was normalized in both EPC- and MSC-treated pigs, while diastolic function (E/A ratio) was restored to normal levels exclusively in RVH + MSCs. RVH-induced myocardial fibrosis and collagen deposition decreased in RVH + EPCs but further decreased in RVH + MSC-treated pigs. Intrarenal delivery of EPCs or MSCs attenuates RVH-induced myocardial injury, yet MSCs restore diastolic function more effectively than EPCs, possibly by greater improvement in renal function or reduction of MCP-1 release from the stenotic kidney. These observations suggest a therapeutic potential for EPCs and MSCs in preserving the myocardium in chronic experimental RVH.
url https://doi.org/10.3727/096368914X685582
work_keys_str_mv AT alfonsoeirin intrarenaldeliveryofmesenchymalstemcellsandendothelialprogenitorcellsattenuateshypertensivecardiomyopathyinexperimentalrenovascularhypertension
AT xiangyangzhu intrarenaldeliveryofmesenchymalstemcellsandendothelialprogenitorcellsattenuateshypertensivecardiomyopathyinexperimentalrenovascularhypertension
AT behzadebrahimi intrarenaldeliveryofmesenchymalstemcellsandendothelialprogenitorcellsattenuateshypertensivecardiomyopathyinexperimentalrenovascularhypertension
AT jamesdkrier intrarenaldeliveryofmesenchymalstemcellsandendothelialprogenitorcellsattenuateshypertensivecardiomyopathyinexperimentalrenovascularhypertension
AT scottmriester intrarenaldeliveryofmesenchymalstemcellsandendothelialprogenitorcellsattenuateshypertensivecardiomyopathyinexperimentalrenovascularhypertension
AT andrejvanwijnen intrarenaldeliveryofmesenchymalstemcellsandendothelialprogenitorcellsattenuateshypertensivecardiomyopathyinexperimentalrenovascularhypertension
AT amirlerman intrarenaldeliveryofmesenchymalstemcellsandendothelialprogenitorcellsattenuateshypertensivecardiomyopathyinexperimentalrenovascularhypertension
AT lilacholermanmdphd intrarenaldeliveryofmesenchymalstemcellsandendothelialprogenitorcellsattenuateshypertensivecardiomyopathyinexperimentalrenovascularhypertension
_version_ 1724601220104978432